XNCR.NASDAQXencor INC

8-K: Xencor Reports Q3 2026 Results, Advances Pipeline

Sentiment:

Quarterly Results


Xencor announced strong third quarter 2026 financial results, driven by significant revenue growth, and provided updates on its promising clinical pipeline, including XmAb819 and plamotamab.

Better than expectedRevenue significantly exceeded the prior year's quarter ($116.5M vs $21.0M).Transitioned from a net loss in Q3 2025 to a net profit in Q3 2026.XmAb819 showed a 45.5% confirmed objective response rate in advanced ccRCC, indicating strong efficacy.Milestone payments from partnerships with Astellas and Zenas BioPharma contributed to revenue.

Summary

  • Xencor reported third quarter 2026 revenue of $116.5 million, a substantial increase from $21.0 million in the same period of 2025, primarily due to royalty and milestone payments.
  • The company's net income for Q3 2026 was $39.4 million, or $0.50 per diluted share, a significant improvement from a net loss of $6.0 million in Q3 2025.
  • Research and development expenses rose to $84.3 million in Q3 2026 from $54.4 million in Q3 2025, reflecting increased development program costs.
  • General and administrative expenses decreased to $9.4 million in Q3 2026 from $14.2 million in Q3 2025, attributed to a legal expense recovery.
  • Xencor expects to end 2026 with $480 million to $500 million in cash and sufficient resources to fund operations into 2029.
  • Key pipeline updates include compelling data for XmAb819 in advanced clear cell renal cell carcinoma (ccRCC) and early dose-escalation data for plamotamab in rheumatoid arthritis.
  • XmAb819 is on track for potential registration-enabling studies, with plans to engage the FDA regarding accelerated approval for advanced ccRCC and initiate a Phase 3 study by the end of 2027.
  • The XENITH-UC Phase 2b study of XmAb942 in ulcerative colitis is on track for primary endpoint analysis in the second half of 2027, with a blinded interim analysis expected around year-end 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth and promising clinical updates, though R&D expenses are increasing.

Positives

  • Significant revenue growth in Q3 2026, reaching $116.5 million compared to $21.0 million in Q3 2025, driven by collaborations, milestones, and royalties.
  • Turnaround to net income of $39.4 million ($0.50/share) in Q3 2026 from a net loss of $6.0 million ($(0.08)/share) in Q3 2025.
  • Strong cash position of $555.7 million as of September 30, 2026, with projected year-end 2026 cash between $480 million and $500 million.
  • Sufficient cash resources are expected to fund operations into 2029.
  • Compelling clinical data presented for XmAb819 in advanced ccRCC, with a 45.5% confirmed objective response rate at the 400 mcg/kg IV dose in an expansion cohort.
  • Xencor has selected the 400 mcg/kg IV dose as the proposed recommended Phase 3 dose for XmAb819.
  • Positive progress in partnership developments, including Amgen's advancement of xaluritamig in Phase 3 studies and Astellas' milestone payment for ASP2138.
  • Zenas BioPharma's submission of a BLA for obexelimab and a marketing authorization application in Japan, triggering milestone payments for Xencor.

Negatives

  • Research and development expenses increased to $84.3 million in Q3 2026 from $54.4 million in Q3 2025, indicating higher investment in pipeline development.
  • Other income, net, decreased to $16.4 million in Q3 2026 from $41.5 million in Q3 2025, primarily due to lower unrealized gains on an equity security.
  • The company reported a net loss of $111.2 million for the nine months ended September 30, 2026, compared to a net loss of $85.3 million for the same period in 2025.

Risks

  • The process of discovering, developing, manufacturing, and commercializing drugs is subject to significant risks.
  • Preliminary clinical trial data may not support continued development or regulatory approval.
  • Risk of loss of key management personnel.
  • The fair value of marketable equity securities may decline.
  • Risks and uncertainties described in Xencor's Form 10-K for the year ended December 31, 2025, and subsequent SEC filings.

Future Outlook

Xencor anticipates accelerating clinical development momentum into 2027, with XmAb819 expected to enter a potential registration-enabling study by the end of 2027. The company projects ending 2026 with $480 million to $500 million in cash and sufficient resources to fund operations into 2029. Initial healthy participant data for XmAb412 is planned for 1H27, and primary endpoint analysis for the XENITH-UC study of XmAb942 is expected in 2H27.

Management Comments

  • "We expect that the accelerating tempo of clinical development for XmAb819, and across our portfolio, may present multiple opportunities for continued momentum into the new year and throughout 2027."
  • "Based on our plans, by the end of 2027 we anticipate XmAb819 will be the third XmAb 2+1 bispecific antibody to enter a potential registration-enabling study, following xaluritamig and ASP2138."
  • "For our autoimmune portfolio, next week at the ACR Convergence conference we will present early dose-escalation data from the Phase 1 study of our CD20 x CD3 B-cell depleting T-cell engager, plamotamab, which we are evaluating in patients with rheumatoid arthritis following standard-of-care treatments."
  • "For our two TL1A-targeting development programs, enrollment in XENITH-UC, the global Phase 2b study of XmAb942, is on track for the primary endpoint analysis in the second half of 2027, and for our novel TL1A x IL23p19 bispecific, XmAb412, we plan to present healthy participant data in the first half of 2027."

Industry Context

StockSavvy.ai notes that Xencor's focus on engineered antibodies, particularly bispecific T-cell engagers and TL1A-targeting therapies, aligns with major trends in oncology and autoimmune disease treatment. The company's progress with XmAb819 in ccRCC and its partnerships with Amgen and Astellas highlight its role in advancing complex biologics within the competitive biopharmaceutical landscape.

Comparison to Industry Standards

  • Xencor's XmAb819 demonstrated a 45.5% confirmed objective response rate in advanced ccRCC, which is competitive for this difficult-to-treat indication, though direct comparisons require specific patient populations and treatment lines.
  • The company's pipeline includes multiple bispecific antibodies, a class of therapeutics that has seen increasing success and investment across the industry, with companies like Amgen and Regeneron also developing similar modalities.
  • The projected cash runway into 2029 is a strong indicator of financial stability, a critical factor for clinical-stage biopharmaceutical companies, many of which face funding challenges.
  • The advancement of partnered programs like xaluritamig (Amgen) and ASP2138 (Astellas) into Phase 3 trials reflects successful collaboration models common in the industry for de-risking and advancing drug candidates.

Stakeholder Impact

  • Shareholders: Potential for increased value due to positive clinical data, strong financial results, and projected cash runway. Milestone payments from partnerships also benefit shareholders.
  • Employees: Continued investment in R&D may lead to job growth and opportunities within the company.
  • Partners (Amgen, Astellas, Zenas BioPharma, Alexion, Incyte): Continued progress in clinical development and regulatory milestones for partnered programs are positive for these entities.
  • Patients: Advancement of XmAb819, plamotamab, XmAb942, and other pipeline candidates offers potential new treatment options for cancer and autoimmune diseases.

Next Steps

  • Engage with the FDA regarding a potential accelerated approval pathway for XmAb819 in advanced ccRCC in 1H27.
  • Initiate a global randomized Phase 3 study evaluating XmAb819 against tivozanib by the end of 2027.
  • Present additional results from the 400 mcg/kg IV cohort of XmAb819 in 1H27.
  • Present results from subcutaneous dose escalation of XmAb819 in advanced ccRCC in 1H27.
  • Present initial data from the first-in-human study of XmAb412 in 1H27.
  • Conduct a blinded interim analysis for the XENITH-UC study around year-end 2026.
  • Reach primary endpoint analysis for the XENITH-UC study in 2H27.
  • Provide an update on progress in the Phase 1 study of XmAb657 in 2H26.

Key Dates

DateDescription
2026-10-01Data-cut for XmAb819 expansion cohort results presented at ESMO 2026 Congress.
2026-11-04Date of Report (earliest event reported).
2026-11-09Presentation of poster on Plamotamab Phase 1 study interim results at ACR Convergence conference.
2026-11-04Xencor reports third quarter 2026 financial results.
2026-12-31Expected year-end 2026 cash, cash equivalents and marketable debt securities projection.
2027-01-01Expected start of funding operations into 2029.
2027-06-30First half of 2027: Presentation of healthy participant data for XmAb412.
2027-12-31End of 2027: Anticipated initiation of a global randomized Phase 3 study for XmAb819.

Recommendation

hold

The company shows strong financial performance and promising clinical data, particularly for XmAb819. However, the significant increase in R&D expenses and the long timelines for many pipeline candidates warrant a cautious 'hold' rating. Investors should monitor clinical trial progress and regulatory interactions closely.

Keywords

XmAb819, ccRCC, plamotamab, rheumatoid arthritis, ulcerative colitis, XmAb942, bispecific antibody, biopharmaceutical

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.